Traws Pharma Future Growth

Future criteria checks 3/6

Traws Pharma is forecast to grow earnings and revenue by 28.8% and 57.6% per annum respectively while EPS is expected to grow by 15.4% per annum.

Key information

28.8%

Earnings growth rate

15.35%

EPS growth rate

Pharmaceuticals earnings growth	11.9%
Revenue growth rate	57.6%
Future return on equity	n/a
Analyst coverage	Low
Last updated	08 May 2026

Recent future growth updates

Recent updates

New Narrative • Apr 30

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Catalysts About Traws Pharma Traws Pharma is a biotechnology company focused on developing next generation antiviral treatments and prophylactic agents for influenza. What are the underlying business or industry changes driving this perspective?

New Narrative • Apr 16

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Catalysts About Traws Pharma Traws Pharma is a clinical stage company focused on developing next generation antiviral treatments and prophylactic therapies for influenza. What are the underlying business or industry changes driving this perspective?

Analysis Article • Mar 09

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Apr 22

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analysis Article • Jul 27

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • Mar 21

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Dec 06

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Earnings and Revenue Growth Forecasts

NasdaqCM:TRAW - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	57	-28	-48	-35	1
12/31/2027	13	-50	-52	-45	2
12/31/2026	N/A	-45	-43	-37	2
12/31/2025	3	7	-21	-18	N/A
9/30/2025	3	-9	-22	-19	N/A
6/30/2025	3	-5	-27	-27	N/A
3/31/2025	0	-35	-31	-31	N/A
12/31/2024	0	-55	-30	-30	N/A
9/30/2024	0	-37	-30	-30	N/A
6/30/2024	0	-41	-23	-23	N/A
3/31/2024	0	-27	-18	-18	N/A
12/31/2023	0	-19	-18	-18	N/A
9/30/2023	0	-20	-17	-17	N/A
6/30/2023	0	-21	-17	-17	N/A
3/31/2023	0	-21	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-17	-17	-17	N/A
6/30/2022	0	-15	-17	-17	N/A
3/31/2022	0	-16	-17	-17	N/A
12/31/2021	0	-16	-19	-19	N/A
9/30/2021	0	-19	-21	-21	N/A
6/30/2021	0	-22	-22	-22	N/A
3/31/2021	0	-25	-23	-23	N/A
12/31/2020	0	-25	-23	-23	N/A
9/30/2020	0	-24	-23	-23	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	2	-19	-21	-21	N/A
12/31/2019	2	-22	-21	-21	N/A
9/30/2019	2	-21	N/A	-21	N/A
6/30/2019	2	-22	N/A	-24	N/A
3/31/2019	1	-23	N/A	-24	N/A
12/31/2018	1	-21	N/A	-23	N/A
9/30/2018	1	-21	N/A	-22	N/A
6/30/2018	1	-23	N/A	-22	N/A
3/31/2018	1	-21	N/A	-23	N/A
12/31/2017	1	-24	N/A	-24	N/A
9/30/2017	1	-23	N/A	-24	N/A
6/30/2017	2	-18	N/A	-19	N/A
3/31/2017	4	-21	N/A	-17	N/A
12/31/2016	6	-20	N/A	-16	N/A
9/30/2016	15	-11	N/A	-16	N/A
6/30/2016	15	-15	N/A	-22	N/A
3/31/2016	13	-19	N/A	-26	N/A
12/31/2015	11	-24	N/A	-31	N/A
9/30/2015	2	-41	N/A	-40	N/A
6/30/2015	0	-50	N/A	-46	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRAW's forecast earnings growth (28.8% per year) is above the savings rate (3.5%).

Earnings vs Market: TRAW's earnings (28.8% per year) are forecast to grow faster than the US market (16.7% per year).

High Growth Earnings: TRAW's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TRAW is forecast to have no revenue next year.

High Growth Revenue: TRAW is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TRAW's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/14 18:40
End of Day Share Price	2026/05/14 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Traws Pharma, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kimberly Lee	Brean Capital Historical (Janney Montgomery)
Michael Thomas Cooper	Edison Investment Research
Etzer Darout	Guggenheim Securities, LLC

Traws Pharma Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target decreased by 22% to US$6.50

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus EPS estimates upgraded to US$0.97 loss

Consensus revenue estimates fall by 13%

Consensus forecasts updated

Price target decreased to US$8.67

Recent updates

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Traws Pharma, Inc. announced that it expects to receive $10 million in funding from Sirenia Capital Management LP

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Traws Pharma, Inc. announced delayed annual 10-K filing

Traws Pharma, Inc. Completes Analysis of Ratutrelvir Clinical Study in Paxlovid-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as A Prophylactic Treatment for Seasonal Influenza

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in Paxlovid-19 Patients

Traws Pharma, Inc. Reports Positive Interim Clinical Data with Ratutrelvir Versus Paxlovid™?, Shows Activity in Paxlovid-Ineligible COVID-19 Patients

Expert Systems Inc. Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma, Inc., Annual General Meeting, Nov 21, 2025

Traws Pharma, Inc. Appoints John Leaman to Its Board of Directors as an Independent Director, Effective October 1, 2025

Traws Pharma, Inc. Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma, Inc. Announces CEO Changes

Traws Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.5142 million.

Traws Pharma Reports Positive Results from an Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Traws Pharma Inc. Announces CFO Changes

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. announced that it expects to receive $72.6 million in funding

Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024

Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Price target decreased by 22% to US$6.50

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Consensus revenue estimates decrease by 19%, EPS upgraded

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Consensus EPS estimates upgraded to US$0.97 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors

Consensus forecasts updated

Price target decreased to US$8.67

Second quarter 2022 earnings: EPS exceeds analyst expectations

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans